Use of etanercept for psoriasis in a liver transplant recipient

Reshmi Madankumar, Lewis Teperman, Jennifer Stein

JAAD Case Reports · 2015 · 21 citations · 6 references

DOIFull text

Open access

Concepts

Abstract

Psoriasis, a chronic cutaneous inflammatory disease, is an immune-mediated disorder caused by complex interactions between dendritic cells, T cells, and keratinocytes. Tumor necrosis factor alfa (TNF-α) is a cytokine that plays a major role in the inflammatory cascade.1 Biologic agents that target TNF-α such as etanercept, infliximab, and adalimumab are effective in the treatment of psoriasis.2

References

6